Physician profile
Amit Sharma
NPI 1295149102
$6,852.66
in general payments reported to CMS, 2019-2025
31 companies · $547 in 2025
The $547 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $412 · 2020: $48.33 · 2021: $29.39 · 2022: $700 · 2023: $2,179 · 2024: $2,938 · 2025: $547.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,663.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,663.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,453.97 | 2022-2024 | Tremfya |
| Sun Pharmaceutical Industries INC. | $687.50 | 2023-2025 | Winlevi, Absorica Ld, Ilumya |
| Abbvie INC. | $668.85 | 2021-2025 | Rinvoq |
| E.R. Squibb & Sons, L.L.C. | $546.49 | 2023-2024 | Sotyktu |
| Galderma Laboratories, L.P. | $328.50 | 2023-2024 | Twyneo, Aklief, Oracea |
| Janssen Scientific Affairs, LLC | $326.66 | 2022-2024 | Tremfya |
| Amgen INC. | $316.50 | 2019-2023 | |
| Ucb, INC. | $250.17 | 2024 | Bimzelx, Cimzia |
| Genzyme Corporation | $231.22 | 2024-2025 | |
| Incyte Corporation | $204.51 | 2024-2025 | Opzelura |
| Pfizer INC. | $202.57 | 2023-2024 | |
| Regeneron Healthcare Solutions, INC. | $199.69 | 2022-2024 | Dupixent |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $198.78 | 2023-2024 | Siliq, Jublia, Duobrii |
| Boehringer Ingelheim Pharmaceuticals, INC. | $192.90 | 2019-2023 | Spevigo, Cyltezo |
| Novartis Pharmaceuticals Corporation | $145.82 | 2019-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $118.18 | 2024 | Vtama |
| Krystal Biotech INC | $100.69 | 2024 | Vyjuvek |
| Lilly USA, LLC | $98.86 | 2019-2025 | Taltz, Ebglyss |
| Novo Nordisk INC | $81.67 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $77.61 | 2019 | |
| Arcutis Biotherapeutics, INC. | $61.51 | 2025 | Zoryve |
| Biofrontera INC. | $56.35 | 2022-2024 | Ameluz, Xepi, Bf-Rhodoled |
| Si-Bone, INC. | $48.33 | 2020 | |
| Kerecis Limited | $45.52 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Helsinn Therapeutics (U.S.), INC. | $41.14 | 2022-2024 | Valchlor |
| Abbott Laboratories | $40.25 | 2019-2022 | |
| Paratek Pharmaceuticals, INC. | $39.20 | 2023 | Nuzyra |
| Janssen Pharmaceuticals, INC | $39.06 | 2019-2025 | Invega Sustenna |
| Collegium Pharmaceutical, INC. | $20.23 | 2025 | Belbuca |
| Allergan, INC. | $16.92 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $13.01 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amit Sharma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.